<DOC>
	<DOCNO>NCT02902536</DOCNO>
	<brief_summary>This study investigator collect plasma cell patient myasthenia gravis purpose find new antibody .</brief_summary>
	<brief_title>Tissue Repository Studies Myasthenia Gravis</brief_title>
	<detailed_description>This bio-specimen collection study . The investigator collect plasma peripheral lymphocyte . Plasma collect either patient undergoes plasma exchange , decision independent study , schedule blood draw . Patient plasma screen novel antibody may cause myasthenia gravis . Subjects found positive candidate antigen myasthenia gravis clinical evaluation consist several disease rating scale perform ( QMG score , MG-composite , Myasthenia Gravis Foundation America ( MGFA ) clinical classification , MG-Quality Life ( QOL ) 15 , MGFA Therapy Status ) .</detailed_description>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<criteria>18 year age old . Clinical Diagnosis MG support evidence either antibody testing , repetitive nerve stimulation study ( RNS ) Single Fiber Electromyography ( EMG ) ( SFEMG ) . Significant medical condition would make participation diagnostic research part evaluation impossible risky . Acute unstable medical condition . Inability provide inform consent , either directly via appoint power attorney . Unwillingness consent collection biological sample cryopreservation . Unable provide evidence previous antibody test neurophysiology confirm diagnosis Myasthenia Gravis . Any bleeding disorder would prevent present danger blood extraction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myasthenia Gravis</keyword>
</DOC>